A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.

Inclusion Criteria:

- Histologically or cytologically documented unresectable stage III NSCLC.

- Documented stable disease or objective response, according to RECIST, after primary
chemoradiotherapy (either sequential or concomitant) for unresectable stage III
disease, within 4 weeks (28 days) prior to randomization.

- Receipt of concomitant or sequential chemoradiotherapy, consisting of a minimum of
two cycles of platinum-based chemotherapy and a minimum radiation dose of ≥ 50 Gy.
Subjects must have completed the primary thoracic chemo-radiotherapy at least four
weeks (28 days) and no later than 12 weeks (84 days) prior to randomization. Subjects
who received prophylactic brain irradiation as part of primary chemo-radiotherapy are
eligible.

- Geographically accessible for ongoing follow-up, and committed to comply with the
designated visits.

- An ECOG performance status of 0-1.

- A Platlet count > 140 x 10(9)/L; WBC > 2.5 x 10(9)/L and hemoglobin > 90 g/L.

Exclusion Criteria:

- Pre-Therapies:

- Undergone lung cancer specific therapy (including surgery) other than primary
chemo-radiotherapy.

- Receipt of immunotherapy (e.g. interferons, tumor necrosis factor [TNF],
interleukins, or biological response modifiers [granulocyte macrophage colony
stimulating factor {GM-CSF}, granulocyte colony stimulating factor {G-CSF},
macrophage-colony stimulating factor {M-CSF}], monoclonal antibodies) within 4
weeks (28 days) prior to randomization.

- Receipt of investigational systemic drugs (including off-label use of approved
products) within 4 weeks (28 days) prior to randomization.

- Disease Status:

- Metastatic disease

- Malignant pleural effusion at initial diagnosis and/or at study entry.

- Past or current history of neoplasm other than lung carcinoma, except for
curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix or
other cancer curatively treated and with no evidence of disease for at least 5
years.

- Autoimmune disease.

- A recognized immunodeficiency disease including cellular immunodeficiencies,
hypogammaglobulinemia or dysgammaglobulinemia; subjects who have hereditary or
congenital immunodeficiencies.

- Any preexisting medical condition requiring chronic steroid or immunosuppressive
therapy (steroids for the treatment of radiation pneumonitis are allowed).

- Known Hepatitis B and/or C.

- Physiological Functions:

- Clinically significant hepatic dysfunction.

- Clinically significant renal dysfunction.

- Clinically significant cardiac disease.

- Splenectomy.

- Infectious process that in the opinion of the investigator could compromise the
subject's ability to mount an immune response.

- Standard Safety:

- Pregnant or breast-feeding women, women of childbearing potential, unless using
effective contraception as determined by the investigator.

- Known drug abuse/alcohol abuse.

- Legal incapacity or limited legal capacity